With 10 vaccine candidates now in phase three trials, one expert predicts another million people worldwide could die within three to six months.One of those vaccine candidates is produced by Novavax. Dr. Gregory Glenn, head of research and development for Novavax, tells NPR he's not concerned about politics tainting the vaccine approval process.While the world waits for a vaccine, NPR science reporter Michaeleen Doucleff reports on a small but growing number of scientists asking: what if we already have a vaccine that could slow the spread of the virus? In participating regions, you'll also hear a local news segment that will help you make sense of what's going on in your community.We're working on an upcoming episode about pandemic precautions and we want to hear from you. Fill out the form on this page and we may follow up on your response. Email us at considerthis@npr.org.